Recursion Pharmaceuticals (NASDAQ:RXRX) Releases Quarterly Earnings Results, Misses Estimates By $0.17 EPS

Recursion Pharmaceuticals (NASDAQ:RXRX) announced its earnings results on Friday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same period in the prior year, the business earned ($0.42) earnings per share. The company’s revenue for the quarter was down 57.8% compared to the same quarter last year.

Recursion Pharmaceuticals Stock Down 4.4 %

Shares of NASDAQ RXRX traded down $0.34 during trading on Friday, reaching $7.34. The company had a trading volume of 29,348,188 shares, compared to its average volume of 25,924,594. Recursion Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $14.12. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average is $7.69 and its 200 day moving average is $7.07. The stock has a market cap of $2.87 billion, a PE ratio of -4.78 and a beta of 0.86.

Analysts Set New Price Targets

A number of brokerages have recently commented on RXRX. KeyCorp decreased their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.